» Articles » PMID: 7495939

The Relationship Between the Control of PH and Healing and Symptom Relief in Gastro-oesophageal Reflux Disease

Overview
Date 1995 Jan 1
PMID 7495939
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Gastro-oesophageal reflux disease (GERD) is generally considered to be the result of a motility disorder which permits the abnormal and prolonged exposure of the lumen of the oesophagus to the acidic gastric contents. This view is supported by experimental data, intra-oesophageal pH measurement, and the dramatic results of symptom relief and healing seen with effective antisecretory treatment. Oesophageal mucosal injury is determined by the pH of the refluxate and duration of acid exposure. Most patients experience meal-stimulated reflux during the day and the more severe cases experience 24-h acid exposure. In contrast to the H2-receptor antagonists (H2RAs), the proton pump inhibitors (PPIs) are more effective at controlling meal-stimulated acid secretion when each is given in standard doses. Therefore, the degree and duration of acid suppression throughout 24 h is greater. Treatments which maintain intra-oesophageal pH > 4 for 96% or more of the 24 h normalize acid exposure and are associated with the highest healing rates. Peptic activity is minimized at or above pH 4. The time above pH 4 is significantly longer with the PPIs than with the H2RAs. Thus, the healing-time curves for GERD (grades II-IV) are shifted to the left for the PPIs which heal a significantly greater proportion of patients earlier than the H2RAs or sucralfate. Symptoms in GERD are related to the degree and duration of oesophageal acid exposure. Symptom relief is more rapid and complete with the PPIs than with the H2RAs or other treatments in standard doses.

Citing Articles

Different dosages of vonoprazan for gastroesophageal reflux disease: study protocol for a pragmatic, crossover-cluster, randomized controlled trial with patient preference arms.

Wang D, Zhou D, Liu X, Xu Z, Bai T, Hou X Trials. 2023; 24(1):778.

PMID: 38041136 PMC: 10691065. DOI: 10.1186/s13063-023-07760-9.


Intragastric pH of foals admitted to the intensive care unit.

Wise J, Raidal S, Wilkes E, Hughes K J Vet Intern Med. 2020; 34(6):2719-2726.

PMID: 32990384 PMC: 7694801. DOI: 10.1111/jvim.15888.


ACVIM consensus statement: Support for rational administration of gastrointestinal protectants to dogs and cats.

Marks S, Kook P, Papich M, Tolbert M, Willard M J Vet Intern Med. 2018; 32(6):1823-1840.

PMID: 30378711 PMC: 6271318. DOI: 10.1111/jvim.15337.


A Randomized, Double-Blind, Pilot Study of the Effect of Famotidine on Acotiamide Treatment for Functional Dyspepsia.

Hojo M, Nagahara A, Asaoka D, Takeda T, Izumi K, Matsumoto K Digestion. 2017; 96(1):5-12.

PMID: 28605740 PMC: 5637310. DOI: 10.1159/000477345.


A randomized, crossover pharmacodynamic study of immediate-release omeprazole/sodium bicarbonate and delayed-release lansoprazole in healthy adult volunteers.

Pratha V, McGraw T, Tobin W Pharmacol Res Perspect. 2016; 4(3):e00238.

PMID: 27433347 PMC: 4876147. DOI: 10.1002/prp2.238.